Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RIDE versus INDERIDE LA 80 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RIDE versus INDERIDE LA 80 50.
HYDRO-RIDE vs INDERIDE LA 80/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Combination of propranolol (non-selective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
One capsule orally once daily, containing propranolol hydrochloride 80 mg (immediate release) and hydrochlorothiazide 50 mg. May be titrated based on response, with maximum propranolol dose 640 mg/day and maximum hydrochlorothiazide dose 50 mg/day.
None Documented
None Documented
Terminal half-life 4-6 hours (prolonged in renal impairment).
Propranolol: 3-6 hours (poor metabolizers up to 10 hours). Hydrochlorthiazide: 6-15 hours (prolonged in renal impairment).
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Renal elimination of propranolol and hydrochlorthiazide: propranolol is extensively metabolized in the liver, <1% excreted unchanged in urine; hydrochlorthiazide is excreted unchanged in urine (≥95% renal).
Category C
Category C
Thiazide Diuretic
Beta Blocker and Thiazide Diuretic